Skip to main content

Table 1 Characteristics of study participants by study and overall

From: Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis

Study

N

Age mean (SD)

Male N. (%)

Smear N. (%)

HIV N. (%)

Ethionamide N. (%)

Ahujan

823

41.4 (12.0)

561 (68.2)

509 (70.8)

488 (74.4)

394 (47.9)

Avenda

72

36.3 (15.3)

43 (59.7)

67 (93.1)

1 (1.4)

13 (18.1)

Burgos

48

47.2 (14.8)

32 (66.7)

36 (75.0)

11 (22.9)

17 (35.4)

Chan

203

42.0 (14.4)

116 (57.1)

203 (100.0)

0 (0.0)

124 (61.1)

Chiang

125

46.1 (15.2)

90 (72.0)

109 (93.2)

0 (0.0)

57 (45.6)

Cox

77

36.9 (11.2)

47 (61.0)

76 (98.7)

0 (0.0)

72 (93.5)

Garcia

47

47.6 (16.4)

26 (55.3)

42 (89.4)

0 (0.0)

22 (46.8)

Granic

104

40.3 (19.5)

61 (58.7)

75 (74.3)

1 (100.0)

47 (45.2)

Koh

155

40.9 (14.4)

82 (52.9)

131 (84.5)

0 (0.0)

74 (47.7)

Lung

99

46.1 (16.2)

74 (74.7)

78 (80.4)

0 (0.0)

47 (47.5)

Migliori

101

39.4 (14.7)

61 (60.4)

80 (79.2)

6 (6.2)

46 (45.5)

Mitnic

732

31.1 (12.0)

436 (59.6)

508 (71.1)

8 (1.2)

495 (67.6)

Narita

81

40.2 (11.8)

55 (67.9)

0 (0.0)

41 (54.7)

26 (32.1)

Palmer

114

35.3 (13.7)

54 (47.4)

108 (94.7)

0 (0.0)

8 (7)

Pasvol

45

36.0 (16.7)

21 (50.0)

29 (74.4)

0 (0.0)

25 (55.6)

Pena

25

41.2 (13.3)

24 (96.0)

25 (100.0)

0 (0.0)

0 (0)

Perez

34

42.1 (12.4)

21 (61.8)

34 (100.0)

0 (0.0)

0 (0)

Quy

157

39.5 (11.4)

121 (77.1)

157 (100.0)

4 (2.5)

0 (0)

Riekstina

1027

42.3 (12.7)

780 (75.9)

269 (68.1)

32 (3.9)

0 (0)

Robert

45

41.7 (15.6)

24 (53.3)

33 (73.3)

9 (25.7)

18 (40.0)

Schaaf

39

7.0 (5.4)

20 (51.3)

9(33.3)

6 (20.7)

30 (76.9)

Seung

1427

43.9 (15.4)

117 (82.4)

142 (100.0)

0 (0.0)

0 (0)

Shim

1364

42.8 (14.9)

1014 (74.3)

927 (68.0)

1 (0.1)

0 (0)

Shin

608

35.8 (11.3)

506 (83.2)

497 (85.8)

5 (0.8)

450 (74.0)

Shirai

61

46.4 (11.9)

46 (75.4)

0 (0.0)

0 (0.0)

40 (65.6)

Tabars

43

44.4 (19.1)

27 (62.8)

42 (97.7)

0 (0.0)

0 (0)

Tupasi

170

39.2 (12.4)

106 (62.4)

107 (67.7)

0 (0.0)

40 (23.5)

Vander

43

32.9 (18.3)

32 (74.4)

0(0.0)

0 (0.0)

1 (2.3)

Vander

2211

36.6 (10.8)

1383 (62.6)

1390 (69.7)

571 (38.4)

2211 (100)

Viiklepp

284

43.0 (13.6)

201 (70.8)

153 (53.9)

9 (3.4)

0 (0)

Yimkim

211

39.3 (15.8)

124 (58.8)

0 (0.0)

0 (0.0)

0 (0)

Median

104

41

63

75

0

41

P25

48

37

59

68

0

0

P75

207

43

74

94

5

51

  1. N.(%): The number and percentage of patients in each study.
  2. Median, P25 and P75 indicates the median, 25th and 75th Percentiles which have been calculated for the number of patients, mean age of patients, proportion of male patients, proportion of smear status, HIV status across studies, and proportion of treatment Ethionamide